INSIGHTS ON CLINICAL TRIAL DESIGN
-
![GettyImages-2152418328-ADC-antibody-drug-conjugate-3d]( "Key Takeaways From ADCs In Oncology Trials Webinar")
Key Takeaways From ADCs In Oncology Trials WebinarBy aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.
-
![citeline connect]( "What Is Citeline Connect?")
What Is Citeline Connect?Explore a centralized patient recruitment platform that enables sponsors to meet their enrollment goals using a diverse selection of channels and recruitment partners.
-
![clinical-trial-payment-GettyImages-2279596023]( "Can Your Trial Payment Approach Stand Up To Regulatory Scrutiny?")
Can Your Trial Payment Approach Stand Up To Regulatory Scrutiny?Fragmented trial payment systems create compliance, ethical, and operational risks. Aligning payments with regulations and ethics improves transparency, reduces burden, and supports audits and participation.
-
![GettyImages-2166551077-AI-Artificial Intelligence-hands]( "AI's Bottleneck In Clinical Trials Moved, And Most People Missed It")
AI's Bottleneck In Clinical Trials Moved, And Most People Missed ItAI has accelerated drug discovery, but the real bottleneck is now clinical trial operations. Explore why regulatory success depends on auditable data governance, not model speed.
-
Why Specialty Lab Samples Are So Vulnerable To Trial Execution Errors7/17/2026
Biomarkers and other specialty lab samples are among the most fragile parts of clinical trial execution, but what makes them so vulnerable to mishandling, and what are the effects?
-
Data Privacy And Trust In China's Clinical Trials2/4/2026
China’s evolving privacy laws are reshaping how global trials operate. Sponsors that prioritize transparency and participant confidence can meet compliance demands while building lasting trust.
-
Decentralized And Community-Based Solutions Driving Women's Healthcare9/24/2025
Clinical trials should reflect the affected population by reducing participation barriers and bringing trials to patients to increase inclusion and improve real-world data.
-
Driving Diversification And Reach With Tech In Community DCTs3/20/2025
Learn how technology, when used correctly, can accelerate trial timelines and drive patient diversification in community-based decentralized clinical trials (DCTs).
-
How Early-Stage Planning Strategies Are Optimizing Drug Development5/12/2025
Early integration of a target product profile (TPP) into early-stage planning is pivotal for steering drug development toward both regulatory success and commercial impact.
CLINICAL TRIAL DESIGN SOLUTIONS
-
![doctors laptop iStock-1196710776]( "Endocrine & Metabolic Expertise To Enable Your Success")
Veristat has built a team of scientific-minded experts who have supported more than 300 projects for endocrine/metabolic disorder treatments and prepared over 30 marketing applications, 60% of which have been approved or authorized to date.
-
![GettyImages-1318863581 patient travel]( "Patient Travel And Logistics")
Block Clinical provides a single point of contact for Patients and Sites who support them throughout their journey, from start to finish.
-
![GettyImages-1204037710 meeting]( "Castor Professional Services: Your Trial Delivery Partner")
Accelerate clinical trial timelines and ensure audit-readiness with expert-led build models, AI-driven data management, and global participant support designed to streamline your path to submission.
-
![GettyImages-165180340-digital-recruitment-people-patients]( "Accelerate Post-Approval Research By Streamlining the Entire Study Lifecycle")
Streamline post-approval research by embedding studies into routine clinical care. Reduce site burden and capture high-quality data for label expansion and regulatory needs.
-
![GettyImages-1441662840-lab-team-communication-collaboration]( "Integrated Programs To Bridge Molecules From Discovery Into Clinical Development")
A new collaboration helps to remove obstacles from the critical path, reduce development risks, eliminate the white space in pre-clinical drug development, and shorten the pathway to clinical development.
